Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 26-Week Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

NCT02973321 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT02973321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02973321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 26-Week Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
December 2, 2016
Completion date
December 27, 2017
Enrollment
296 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus